GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Theralink Technologies THER · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Theralink Technologies — daily THER Delayed
Market value
$615,150
Last close × shares
Volume
110
Shares, 30 Oct 2026

About Theralink Technologies

Its shares trade under the ticker THER. It has been listed since 23 April 2007. In the fiscal year to 30 September 2023, it reported revenue of $606,796 and a net loss of $30.9m. At that date it held total assets of $2.8m and shareholders' equity of −$38.1m.

Theralink Technologies, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. The company is headquartered in Baton Rouge, Louisiana. The company went IPO on 2007-04-23. The Company, through its phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. In addition to the Company’s first assay for advanced breast cancer, the Company is working on a second assay, which is pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, and prostate, among others. The company provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration (FDA)-approved and investigational drug treatments. The Company’s applications are across multiple cancer types, including but not limited to, breast, non-small cell lung, colorectal and pancreatic.

Figures and description from our data supplier, not checked against the company's own report.

More about Theralink Technologies →

How it makes its money

Revenue, year to 30 Sept 2023

  • Biopharma Services [Member[ $465,430 · 76.7%
  • Patient Testing Service [Member] $141,366 · 23.3%

Latest on Theralink Technologies

Our reporting

We have not reported on Theralink Technologies yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Theralink Technologies's ticker?

Theralink Technologies trades as THER on its US listing, under ISIN US88339Q1094.

What was Theralink Technologies's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.